Please login to the form below

Not currently logged in
Email:
Password:

Gilead EVP, Kevin Young, receives CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE "for services to the healthcare and pharmaceutical industries particularly to the development and marketing of life-changing medicines."
 
Young, originally from the north of England, is based at Gilead Sciences in California. Gilead provides the most frequently chosen antiretroviral medicines for the treatment of HIV in the developed world – the life-changing medicines referred to in the CBE citation.

Kevin Young, EVP Gilead Sciences
Kevin Young, EVP Gilead Sciences

 
Gilead's International Access Operations provide these medicines at a no-profit price to almost 100 low-income countries and at sharply discounted prices in a total of 130 developing countries. In total, 2.1 million people worldwide receive one of Gilead's HIV treatments, two thirds (1.4 million) are in the developing world. 

In the UK and Europe, Gilead is well known for Atripla (efavirenz tenofovir emtricitabine): its single tablet regimen (STR) for the treatment of HIV. Atripla is the only single tablet taken once a day that contains the triple-therapy required to successfully control the HIV virus and prevent progression to AIDS.  

13th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics